Brief: Dermapharm FY Adjusted EBITDA EUR 310.2 Million
14/03/2024 06:31
Mar 14 (Reuters) - Dermapharm FY EBITDA margin 24.7%. * FY adjusted EBITDA margin 27.3% * FY EBITDA EUR 280.3 million * FY revenue EUR 1,135.4 million vs. IBES estimate EUR 1,117 million
Recent news on Dermapharm Holding SE
See all newsBrief: Dermapharm Confirms 2026 Forecast
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit